W. Bains, Associate Faculty, Institute of Technology, University of Cambridge, UKWilliam was educated in London, and at Oxford where he gained a 1st in biochemistry. After a PhD at Warwick and Postdoc at Stanford,
California, William held a lectureship at University of Bath, researching inter alia genomics and bioinformatics technologies and what
is now called 'functional genomics'. In 1988 he joined a technology consultancy, developing new life-science based technologies such
as sequencing by hybridization (which he co-invented), and evaluating new technology opportunities in biotech. and pharmaceuticals.
In October 1996 he joined Merlin Ventures to head the science team co-founding and funding new bioscience companies in the UK. The science
team was responsible for identifying the core science, planning how it is to be developed, and providing interim management as the company
grew, for eight start-up companies in areas as diverse as CNS gene therapy and domestic baby monitors. William wrote most of the first
round business plans for Cyclacel, Eurogene (now ARK Therapeutics), PanTherix.
In 1999 William was the co-founder of Amedis Pharmaceuticals
Ltd with Prof. John Caldwell (Imperial College). Amedis is a world-class drug discovery company, developing new chemical and computational
technologies to improve the success rate in development of new medicines. William created the concept and the company, and took it from
concept through two funding rounds to an established company with a strong management team, two technology platforms, two Pharmaceutical
company collaborations, and exciting product development programmes.
In 2002 William founded Delta G Ltd., a company exploring a
'systems biology' approach to diseases of energy metabolism.
William's expertise has been recognised with Toshiba Year of Invention
prize in 1992, election to Human Genome Organisation in 1994, and appointment as a visiting Professor at Imperial College, London in
1999. He is author of numerous papers, patents, and three books. |